XNAS
NTHI
Market cap65mUSD
Oct 08, Last price
2.53USD
1D
-6.64%
1Q
-43.65%
IPO
-78.92%
Name
NeOnc Technologies Holdings Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
40k
-51.82%
Net income
-62m
L+422.30%
CFO
-20m
L+383.25%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. It develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company was founded in 2008 and is headquartered in Calabasas, CA.
Key people
Thomas Chen
Chief Medical Officer, Chief Scientific Officer, Director · since 2025
Keithly Garnett
Chief Financial Officer · since 2024
Patrick Walters
Chief Operating Officer · since 2023
Amir Heshmatpour
Executive Chairman of the Board, President, Chief Executive Officer · since 2025
Josh Neman
Chief Clinical Officer · since 2025
Ming-Fu Chiang
Director · since 2025
Ming-Fu Chiang
Director · since 2025
Bader Almonawer
Lead Independent Director · since 2025
Jim Delshad
Independent Director · since 2025
Steven Giannotta
Independent Director · since 2025
Victoria Medvec
Independent Director · since 2025
Valuation
Title in thousands, except ratios and share amounts | FY | FY |
|---|---|---|
| 2025‑12 | 2024‑12 | |
| Income | ||
Revenues | ||
Cost of revenue | ||
Unusual Expense (Income) | ||
NOPBT | ||
NOPBT Margin | ||
Operating Taxes | ||
Tax Rate | ||
NOPAT | ||
Net income | ||
Dividends | ||
Dividend yield | ||
Proceeds from repurchase of equity | ||
BB yield | ||
| Debt | ||
Debt current | ||
Long-term debt | ||
Deferred revenue | ||
Other long-term liabilities | ||
Net debt | ||
| Cash flow | ||
Cash from operating activities | ||
CAPEX | ||
Cash from investing activities | ||
Cash from financing activities | ||
FCF | ||
| Balance | ||
Cash | ||
Long term investments | ||
Excess cash | ||
Stockholders' equity | ||
Invested Capital | ||
ROIC | ||
ROCE | ||
| EV | ||
Common stock shares outstanding | ||
Price | ||
Market cap | ||
EV | ||
EBITDA | ||
EV/EBITDA | ||
Interest | ||
Interest/NOPBT |